Stoke Therapeutics to Present at Upcoming Investor Conferences in June
May 28, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--May 28, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 18, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--May 18, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026
– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the dise ...Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
April 30, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 30, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 16, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 16, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 8, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
April 7, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 7, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
March 17, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 17, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in D ...
March 4, 2026
–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with t ...Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 24, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 18, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 18, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicin ...
February 11, 2026
–Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– –Changes in visual ...Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 4, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 16, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 16, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicate ...Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from ...
January 11, 2026
— Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA ...Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 6, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated ...